BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 24682512)

  • 1. p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q).
    Saft L; Karimi M; Ghaderi M; Matolcsy A; Mufti GJ; Kulasekararaj A; Göhring G; Giagounidis A; Selleslag D; Muus P; Sanz G; Mittelman M; Bowen D; Porwit A; Fu T; Backstrom J; Fenaux P; MacBeth KJ; Hellström-Lindberg E
    Haematologica; 2014 Jun; 99(6):1041-9. PubMed ID: 24682512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities.
    Möllgård L; Saft L; Treppendahl MB; Dybedal I; Nørgaard JM; Astermark J; Ejerblad E; Garelius H; Dufva IH; Jansson M; Jädersten M; Kjeldsen L; Linder O; Nilsson L; Vestergaard H; Porwit A; Grønbæk K; Hellström-Lindberg E
    Haematologica; 2011 Jul; 96(7):963-71. PubMed ID: 21719884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lenalidomide in patients with red blood cell transfusion-dependent myelodysplastic syndrome and del(5q): a single-centre "real-world" experience.
    Cerqui E; Pelizzari A; Schieppati F; Borlenghi E; Pagani C; Bellotti D; Lamorgese C; Boiocchi L; Sottini A; Imberti L; Rossi G
    Leuk Lymphoma; 2015; 56(11):3129-34. PubMed ID: 25811676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic Outcomes and Prognostic Impact of Gene Mutations Including TP53 and SF3B1 in Patients with Del(5q) Myelodysplastic Syndromes (MDS).
    Chan O; Ali NA; Sallman D; Padron E; Lancet J; Komrokji R
    Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):e467-e476. PubMed ID: 35101379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression.
    Jädersten M; Saft L; Smith A; Kulasekararaj A; Pomplun S; Göhring G; Hedlund A; Hast R; Schlegelberger B; Porwit A; Hellström-Lindberg E; Mufti GJ
    J Clin Oncol; 2011 May; 29(15):1971-9. PubMed ID: 21519010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes.
    Giagounidis A; Mufti GJ; Fenaux P; Germing U; List A; MacBeth KJ
    Ann Hematol; 2014 Jan; 93(1):1-11. PubMed ID: 24018623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion.
    Sebaa A; Ades L; Baran-Marzack F; Mozziconacci MJ; Penther D; Dobbelstein S; Stamatoullas A; Récher C; Prebet T; Moulessehoul S; Fenaux P; Eclache V
    Genes Chromosomes Cancer; 2012 Dec; 51(12):1086-92. PubMed ID: 22933333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations.
    Scharenberg C; Giai V; Pellagatti A; Saft L; Dimitriou M; Jansson M; Jädersten M; Grandien A; Douagi I; Neuberg DS; LeBlanc K; Boultwood J; Karimi M; Jacobsen SE; Woll PS; Hellström-Lindberg E
    Haematologica; 2017 Mar; 102(3):498-508. PubMed ID: 27884971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q).
    Fenaux P; Giagounidis A; Selleslag D; Beyne-Rauzy O; Mittelman M; Muus P; Nimer SD; Hellström-Lindberg E; Powell BL; Guerci-Bresler A; Sekeres MA; Deeg HJ; Del Cañizo C; Greenberg PL; Shammo JM; Skikne B; Yu X; List AF
    J Hematol Oncol; 2017 Jun; 10(1):131. PubMed ID: 28651604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression.
    Jädersten M; Saft L; Pellagatti A; Göhring G; Wainscoat JS; Boultwood J; Porwit A; Schlegelberger B; Hellström-Lindberg E
    Haematologica; 2009 Dec; 94(12):1762-6. PubMed ID: 19797731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lenalidomide for del(5q) and non-del(5q) myelodysplastic syndromes.
    Giagounidis AA
    Semin Hematol; 2012 Oct; 49(4):312-22. PubMed ID: 23079061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study.
    Giagounidis A; Mufti GJ; Mittelman M; Sanz G; Platzbecker U; Muus P; Selleslag D; Beyne-Rauzy O; te Boekhorst P; del Cañizo C; Guerci-Bresler A; Nilsson L; Lübbert M; Quesnel B; Ganser A; Bowen D; Schlegelberger B; Göhring G; Fu T; Benettaib B; Hellström-Lindberg E; Fenaux P
    Eur J Haematol; 2014 Nov; 93(5):429-38. PubMed ID: 24813620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A decade of progress in myelodysplastic syndrome with chromosome 5q deletion.
    List A; Ebert BL; Fenaux P
    Leukemia; 2018 Jul; 32(7):1493-1499. PubMed ID: 29445113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CSNK1A1 mutations and isolated del(5q) abnormality in myelodysplastic syndrome: a retrospective mutational analysis.
    Smith AE; Kulasekararaj AG; Jiang J; Mian S; Mohamedali A; Gaken J; Ireland R; Czepulkowski B; Best S; Mufti GJ
    Lancet Haematol; 2015 May; 2(5):e212-21. PubMed ID: 26688096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of the type of 5q loss with complex karyotype, clonal evolution, TP53 mutation status, and prognosis in acute myeloid leukemia and myelodysplastic syndrome.
    Volkert S; Kohlmann A; Schnittger S; Kern W; Haferlach T; Haferlach C
    Genes Chromosomes Cancer; 2014 May; 53(5):402-10. PubMed ID: 24493299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Higher-risk myelodysplastic syndromes with del(5q): does the del(5q) matter?
    Gorshein E; Weber UM; Gore S
    Expert Rev Hematol; 2020 Mar; 13(3):233-239. PubMed ID: 32067540
    [No Abstract]   [Full Text] [Related]  

  • 17. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.
    Göhring G; Giagounidis A; Büsche G; Kreipe HH; Zimmermann M; Hellström-Lindberg E; Aul C; Schlegelberger B
    Ann Hematol; 2010 Apr; 89(4):365-74. PubMed ID: 19855965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes.
    Komrokji RS; List AF
    Ann Oncol; 2016 Jan; 27(1):62-8. PubMed ID: 26504152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients.
    Caceres G; McGraw K; Yip BH; Pellagatti A; Johnson J; Zhang L; Liu K; Zhang LM; Fulp WJ; Lee JH; Al Ali NH; Basiorka A; Smith LJ; Daugherty FJ; Littleton N; Wells RA; Sokol L; Wei S; Komrokji RS; Boultwood J; List AF
    Proc Natl Acad Sci U S A; 2013 Oct; 110(40):16127-32. PubMed ID: 24043769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myelodysplastic syndromes del(5q): Pathogenesis and its therapeutic implications.
    Bruzzese A; Martino EA; Mendicino F; Lucia E; Olivito V; Capodanno I; Neri A; Morabito F; Vigna E; Gentile M
    Eur J Haematol; 2024 Jun; 112(6):860-869. PubMed ID: 38294126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.